|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | G01N 33/543 | |
| G01N 33/566 | |||
| G01N 33/574 | |||
| G01N 33/68 |
| (11) | Patento numeris | 3283882 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 16780526.6 |
| Europos patento paraiškos padavimo data | 2016-04-12 | |
| (97) | Europos patento paraiškos paskelbimo data | 2018-02-21 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2020-12-16 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/US2016/027014 |
| Data | 2016-04-12 |
| (87) | Numeris | WO 2016/168133 |
| Data | 2016-10-20 |
| (30) | Numeris | Data | Šalis |
| 201562149333 P | 2015-04-17 | US |
| (72) |
AYERS, Mark, US
LUNCEFORD, Jared, US
LOBODA, Andrey, US
NEBOZHYN, Michael, US
MCCLANAHAN, Terrill, K., US
HIRSCH, Heather, US
|
| (73) |
Merck Sharp & Dohme Corp.,
126 East Lincoln Avenue, Rahway, NJ 07065-0907,
US
|
| (54) | BLOOD-BASED BIOMARKERS OF TUMOR SENSITIVITY TO PD-1 ANTAGONISTS |
| BLOOD-BASED BIOMARKERS OF TUMOR SENSITIVITY TO PD-1 ANTAGONISTS |